Australia's ChemGenex Gets Setback For Leukemia Drug In U.S.
This article was originally published in PharmAsia News
Executive Summary
ChemGenex of Australia was rebuffed by the U.S. FDA in a quest for approval of Omapro (omacetaxine) for treating chronic myeloid leukemia